Results 31 to 40 of about 29,860 (191)

Drug-drug interactions between antiretrovirals and bedaquiline [PDF]

, 2017
Tuberculosis (TB) is a leading cause of morbidity and mortality worldwide. People living with HIV are particularly susceptible to TB infection, and treatment of HIV-TB co-infection is challenging for multiple reasons, including potential drug ...
Pandie, Mishal
core   +1 more source

A Review of Tuberculosis: Focus on Bedaquiline

, 2013
PURPOSE: The history and prevalence of tuberculosis and the role of bedaquiline in multidrug-resistant (MDR) tuberculosis are reviewed. SUMMARY: Tuberculosis continues to cause significant morbidity and mortality worldwide.
Chan, Bonnie, Brown, Jack, Khadem, Tina M.   +2 more
core   +2 more sources

Use of bedaquiline in spinal osteomyelitis and soft tissue abscess caused by multidrug-resistant Mycobacterium tuberculosis: A case report

Brazilian Journal of Infectious Diseases, 2022
Introduction: Spinal Tuberculosis (STB) represents between 1% and 2% of total tuberculosis cases. STB management remains challenging; the first-line approach consists of medical treatment, while surgery is reserved for patients with complications.
Andrea De Vito, Vito Fiore, Valentina Urru, Elena Bozzi, Nicholas Geremia, Elija Princic, Donatella Canu, Paola Molicotti, Riccardo Are, Sergio Babudieri, Giordano Madeddu   +10 more
doaj   +1 more source

Bedaquiline-associated parameter ranges.

, 2016
Bedaquiline-associated parameter ranges.
Frank G. Cobelens (629970), Amber Kunkel (3208332), Ted Cohen (118302)   +2 more
core   +1 more source

In vitro activity of bedaquiline against slow-growing nontuberculous mycobacteria.

, 2019
<p>Bedaquiline (BDQ) is a recently approved antibiotic for the treatment of multidrug-resistant tuberculosis, but its potential against slow-growing mycobacteria (SGM) is still unknown.
A. Martin, Torres Godino, Isabel, Mathys, Vanessa, Aguilar-Ayala, Diana Angelica, V. Mathys, I. Torres Godino, N. Lounis, Lounis, Nacer, D.A. Aguilar-Ayala, V.,Hector Rodriguez, Rodriguez-Villalobos, Hector, Martin, Anandi   +11 more
core   +1 more source

A Bayesian approach to estimate the probability of resistance to bedaquiline in the presence of a genomic variant.

PLoS ONE, 2023
BackgroundBedaquiline is a core drug for treatment of rifampicin-resistant tuberculosis. Few genomic variants have been statistically associated with bedaquiline resistance.
Degefaye Zelalem Anlay, Emmanuel Rivière, Pham Hien Trang Tu, Steven Abrams, Annelies Van Rie   +4 more
doaj   +1 more source

Inhibitory effect of carvedilol on bedaquiline metabolism in vitro and in vivo [PDF]

PeerJ
Bedaquiline has recently been approved for the treatment of multidrug-resistant tuberculosis. Carvedilol is a cardiovascular medication extensively used in the treatment of heart failure and hypertension.
Qingqing Li, Wanshu Li, Jie Chen, Hangjuan Lin, Cixia Zhou   +4 more
doaj   +2 more sources

Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin-resistant tuberculosis [PDF]

, 2022
Aims: We aimed to explore the effect of pregnancy on bedaquiline pharmacokinetics (PK) and describe bedaquiline exposure in the breast milk of mothers treated for rifampicin-resistant tuberculosis (TB), where there are no human data available.
Loveday, M, McIlleron, Helen, Mkhize, Buyisile, McIlleron, H, Paolo Denti, Gausi, Kamunkhwala, Helen McIlleron, Marian Loveday, Denti, P, Catriona Waitt, Maartens, G, Wiesner, Lubbe, Kamunkhwala Gausi, Richard Court, Maartens, Gary, Loveday, Marian, Lubbe Wiesner, Gary Maartens, Mkhize, B, Waitt, Catriona, Denti, Paolo, Buyisile Mkhize, Court, R, Waitt, C, Court, Richard, Gausi, K, Wiesner, L   +26 more
core   +1 more source

Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis

The Lancet Microbe, 2021
Summary: Background: Bedaquiline is a crucial drug for control of rifampicin-resistant tuberculosis. Molecular drug resistance assays could facilitate effective use of bedaquiline and surveillance of drug resistance emergence.
Nabila Ismail, PhD, Emmanuel Rivière, MSc, Jason Limberis, PhD, Stella Huo, MSc, John Z Metcalfe, ProfPhD, Rob M Warren, ProfPhD, Annelies Van Rie, ProfPhD   +6 more
doaj   +1 more source

Bedaquiline in the treatment of extensively drugresistant tuberculosis

Медицинский совет, 2022
Introduction. Extensive drug resistance (XDR) M. Tuberculosis (MBT) is considered the main factor that reduces the effectiveness of the treatment of TB patients around the world, including Russia.
T. I. Morozova, N. P. Doktorova, O. N. Otpushchennikova, N. Yu. Nikolenko   +3 more
doaj   +1 more source